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Background: Mutations in epigenetic modifiers were reported in patients with acute myeloid leukaemia (AML)
including mutations in DNA methyltransferase 3A gene (DNMT3A) in 20%-30% patients and mutations in isocitrate
dehydrogenase 1/2 gene (IDH1/2) in 5%-15% patients. Novel studies have shown that mutations in DNMT3A and
IDH1/2 influence prognosis, indicating an increasing need to detect these mutations during routine laboratory analysis.
DNA sequencing for the identification of these mutations is time-consuming and cost-intensive. This study aimed to
establish rapid screening tests to identify mutations in DNMT3A and IDH1/2 that could be applied in routine laboratory
procedures and that could influence initial patient management.
Methods: In this study we developed an endonuclease restriction method to identify the most common DNMT3A
mutation (R882H) and an amplification-refractory mutation system (ARMS) to analyse IDH2 R140Q mutations. Furthermore,
we compared these methods with HRM analysis and evaluated the latter for the detection of IDH1 mutations.
Results: Of 230 samples from patients with AML 30 (13%) samples had DNMT3A mutations, 16 (7%) samples had IDH2
R140Q mutations and 36 (16%) samples had IDH1 mutations. Sensitivity assays performed using serial dilutions of
mutated DNA showed that ARMS analysis had a sensitivity of 4.5%, endonuclease restriction had a sensitivity of 0.05%
and HRM analysis had a sensitivity of 5.9%–7.8% for detecting different mutations. HRM analysis was the best screening
method to determine the heterogeneity of IDH1 mutations. Furthermore, for the identification of mutations in IDH2 and
DNMT3A, endonuclease restriction and ARMS methods showed a perfect concordance (100%) with Sanger sequencing
while HRM analysis showed a near-perfect concordance (approximately 98%).
Conclusion: Our study suggested that all the developed methods were rapid, specific and easy to use and interpret.
HRM analysis is the most timesaving and cost-efficient method to rapidly screen all the 3 genes at diagnosis in samples
obtained from patients with AML. Endonuclease restriction and ARMS assays can be used separately or in combination
with HRM analysis to obtain more reliable results. We propose that early screening of mutations in patients with AML
having normal karyotype could facilitate risk stratification and improve treatment options.
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Acute myeloid leukaemia (AML) is a clonal disorder char-
acterised by the accumulation of myeloid cells and impair-
ment of normal haematopoiesis [1]. The recent large-scale
sequencing of AML genomes is now providing opportun-
ities for patient stratification and personalised approaches
to treatments that are based on an individual’s mutation* Correspondence: rimma.berenstein@charite.de
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article, unless otherwise stated.profiles [1-3]. A few recurring gene mutations and overex-
pressed genes having prognostic relevance in AML have
been identified and incorporated in the current prognosti-
cation models.
Recently, a new class of mutations affecting genes for
DNA methylation and post-translational histone modifica-
tion was identified in AML. These mutations frequently
occur in the DNA nucleotide methyltransferase 3A gene
(DNMT3A) [4-8] and isocitrate dehydrogenase 1/2 gene
(IDH1/2) (isocitrat dehydrogenase 1/2) [9-13]. DNMT3Atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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which also includes DNTM1, DNMT3B and DNMT3L.
Methyltransferases modify methylation patterns by enzy-
matically adding a methyl group to cytosine residues in
CpG islands and are involved in tissue-specific gene expres-
sion [4,14]. Studies in different AML cohorts have reported
the incidence of DNMT3A mutations in up to 22% de novo
AML and 36% cytogenetically normal AML samples [5,6].
Nonsense, frameshift and missense mutations commonly
occur in DNMT3A; however a point mutation at position
R882 is the most frequently (40%–60%) observed mutation
[7]. In vitro studies suggest that mutations at this position
disturb the formation of heterodimers with DNMT3L,
thereby preventing the catalytic activity of DNMT3A. Dif-
ferent studies have shown a negative impact of DNMT3A
mutation on outcomes in patients with AML [3,15-19].
Prognostic effect is known to depend on certain biological
factors as well as a combination of cytogenetics and other
mutations such as those in FLT3 and NPM1 [3,6,8].
Somatic mutations in IDH1/2 occur in 5–30% patients
with AML and are commonly associated with nucleophos-
min 1 (NPM1) mutations [9,10]. Both the genes play a
critical role in the citric acid cycle IDH1 in the cytoplasm
and peroxisome and IDH2 in the mitochondria. Both
IDH1 and IDH2 promote the conversion of isocitrate to α-
ketoglutarate (α-KG) that is associated with the reduction
of nicotinamide adenine dinucleotide phosphate (NADP+)
to NADPH [8,11,20]. Mutations in IDH1 and IDH2 are
heterozygous and occur in highly conserved arginine resi-
dues (IDH1 R132 and IDH2 R140/R172). Mutations at
IDH2 R140 always result in the conversion of arginine
to glutamine, whereas substitutions at IDH1 R132 and
IDH2 R172 result in a wide range of amino acid replace-
ments [12]. All point mutations in IDH1/2 lead to a gain
of function, enabling the conversion of α-KG to 2-
hydroxyglutarate (2-HG) and oxidation of NADPH to
NADP+. Furthermore, an increase in 2-HG-levels leads to
the functional impairment of α-KG-dependent enzymes
through competitive inhibition [13].
In contrast to the impact of DNMT3A mutations, the
impact of IDH1/2 mutations on prognosis is not com-
pletely understood. It appears that prognosis may depend
on specific patient populations and a combination with
NPM1 mutations [21-23].
The increasing evidence of high incidence particularly in
cytogenetically normal AML and prognostic pertinence of
DNMT3A and IDH1/2 mutations support the need to
identify these mutations in routine diagnostic screening.
Importantly, the presence of DNMT3A and IDH1/2 muta-
tions may confer sensitivity to novel therapeutic approaches,
including demethylating agents [24,25].
The current available methods like direct sequencing
are informative but time consuming and cost intensive.
In this study, we validated the polymerase chain reaction(PCR)-based high resolution melt (HRM) assay for
screening DNMT3A, IDH1 and IDH2 mutations in sam-
ples obtained from patients with AML at diagnosis and
developed 2 rapid methods for detecting more common
mutations, DNMT3A R882H and IDH2 R140Q. We evalu-
ated the utility of endonuclease restriction-based detection
method to identify mutations in DNMT3A and designed
an amplification-refractory mutation system (ARMS) to
detect mutations in IDH2. In addition we compared both




Bone marrow (BM) samples from 230 patients with newly
diagnosed AML were included in the study. All patients
were treated at the University Clinic Charité, Campus
Benjamin Franklin, from May 2000 to July 2013. Patient’s
characteristics are summarised in the Additional file 1:
Table S1. The male/female ratio of the study population
was 116/114, and the median age was 57 years (range, 16–
94 years). Diagnoses were established according to the
WHO criteria [26]. Written informed consent was obtained
from all patients in accordance with the Declaration of
Helsinki and the ethical guidelines of the Charite University
School of Medicine, which approved this study.
DNA extraction
Mononuclear cells from BM aspirates were isolated
using Ficoll density gradient centrifugation as described
[27]. DNA was extracted using Allprep DNA/RNA mini
kit (Qiagen) as per the manufacturer’s instructions.
ARMS analysis of IDH2-R140Q mutations
All primers were designed using Primer 3 Software
(Additional file 2: Table S2). ARMS analysis was per-
formed using 2 control primers flanking exon 23 and 2
allele-specific primers IDH2-RI and IDH2-FI that are
complementary to the wild-type (wt) and mutated alleles,
respectively. To enhance specificity, both the primers had
an additional medium mismatch at the preliminary base.
The PCR mixture and reaction conditions are specified in
the Additional file 3: PCR reaction mixtures and condi-
tions. The generated PCR products were analysed on a
1.5% agarose gel.
Endonuclease restriction analysis of DNMT3A-R882H
mutations
PCR amplification for endonuclease restriction analysis was
conducted using primers DNMT3A-ResF/R (Additional
file 2: Table S2). PCR reaction mixture was prepared as
that described for ARMS assay. The reaction conditions
are specified in the Additional file 3. In all, 10 μl of the
PCR product was directly applied for endonuclease
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(New England Biolabs). After incubation at 37°C for
15 min products were analysed on a 1.5% agarose gel
containing 10% ethidium bromide (voltage 150 V).
HRM assay
The reaction mixture and HRM conditions are specified
in the Additional file 3. The analysis was performed in a
Rotor Gene 6000 Real-Time PCR Cycler (Qiagen). Sam-
ples, including a control sample for each mutation and
wt allele, were analysed in duplicates. For DNMT3A and
IDH2, the wt allele was used for normalisation, while for
IDH1 R132C mutation control was used as the baseline.
Normalisation regions for the optimal detection of
DNMT3A were 82°C-83°C (leading range) and 87°C-88°C
(trailing range), for the optimal detection of IDH1 were
73°C-74°C (leading range) and 82°C-83°C (trailing range)
and for the optimal detection of IDH2 were 77°C-78°C
(leading range) and 87°C-88°C (trailing range). Confidence
threshold was set to 70% for all the genes.
DNA sequencing
All the primers used for sequencing are listed in the
Additional file 2: Table S2. All PCR reaction conditions
are specified in the Additional file 3. The obtained prod-
ucts were purified using the PCR Purification Kit (Qiagen),
as described in the manual. Sequencing reaction was per-
formed using Big Dye Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems). The sequencing products were
purified using DyeEx 2.0 Spin Kit (Qiagen) according to the
manufacturer’s instructions. The purified products wereFigure 1 Restriction analysis of DNMT3A R882H mutations. 1) Agarose
and 2 negative (54, 143) patients. Wt samples showed 2 bands at 190 bp a
114 bp because of the loss of a restriction site of Fnu4HI caused by the mutat
sequence analysis of patient 187 showing heterozygote mutation CGC to CACdiluted with 18 μl HiDi-Formamid (Applied Biosystems),
incubated at 95°C for 3 min and chilled on ice for 3 min.
Sequencing was performed using ABI310 Genetic Analyser
(Applied Biosystems), and data were collected using ABI
Prism 310 Data Collection Software.
Results and discussion
All the positive and negative controls used in this study
were selected by Sanger sequencing of patients’ samples.
The results obtained using endonuclease restriction,
ARMS and HRM were verified with those obtained using
Sanger sequencing to determine the specificity of the as-
says. Sensitivity was measured as the minimal percentage
of mutated allele in a sample detected by the assay. The
initial portion of mutation was determined using Sanger
sequencing.
DNMT3A mutation analysis
Endonuclease restriction analysis identified DNMT3A
R882H G>A mutations in 28 out of 230 patients with
AML (12.2%) and HRM analysis identified 2 additional
R882X G>C mutations (0.9%), which are consistent with
the frequency published by Lin et al. [28]. The age of the
patients ranged from 24 to 87 years (median, 58 years).
Among these patients, 53% had a normal karyotype.
None of the patients in the prognostic favourable group
had DNMT3A mutations. Of 30 patients, 16 had FLT3
mutations.
Figure 1 provides a representative result of restriction
analysis with 5 positive and 2 negative samples. Point mu-
tation at R882H (GCCGC to GCCAC) led to the loss ofgel analysis of restricted products of 5 positive (12, 34, 57, 65, 187)
nd 114 bp. Positive samples showed 3 bands at 289 bp, 190 bp,
ion. Hyperladder II (Bioline) was used as the marker. 2) Representative
.
Figure 2 Sensitivity analysis of DNMT3A R882H detection. 1) Endonuclease restriction analysis of serial dilutions of DNMT3A R882H; Undiluted
mutation ratio was 59% (estimated by sequencing). Mutated allele wa detected up to a degree of 0.05%. 2) Difference plot for HRM analysis of serial
dilutions of DNMT3A R882H: Correct estimation was possible up to a mutation ratio of 5.9%; lower mutation ratios were identified false-negative.
Normalisation was performed to the wt allele.
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289 bp fragment. Because of heterozygosity, the 190 bp wt
fragment and the smaller 114 bp fragment are present in
every sample. Sensitivity of the assay was analysed using
serial dilutions of wt and DNMT3A R882H-mutated DNA
(initial mutation ratio in Sanger sequencing was 59%,
Figure 2.1). The fragment containing the mutation was
explicitly apparent with a mutational content of 0.05%,
indicating a very high sensitivity of the assay. In addition
mutations in exon 23 of DNMT3A were detected using
HRM analysis. Results of HRM analysis were plotted as a
difference in the fluorescence of the tested sample versus
that of a wt control (normalisation line), referred to
as a temperature-shifted difference plot (Figure 3.1).
Discrepancies between mutated and wt samples could also
be observed in the melting plot profiles. Sample contain-
ing R882H mutation showed 2 peaks at 84.5°C and 85.6°C,
whereas the wt samples showed only 1 peak at 85.7°C.
Compared to the wt allele, R882X allele was slightly shifted
to the left, with a melting temperature of 85.6°C (Figure 3.2).Figure 3 HRM analysis of DNMT3A mutations. 1) Difference plot for HRM
was performed to the wt allele. R882X showed a right-shifted peak compared t
wt allele. Vertical axis corresponds to changes in the fluorescence signal over tim
allele had only one peak at 85.7°C. R882X G>C had a left shifted peak at 85.6°C.Sensitivity of the HRM assay was assessed similar to that of
restriction analysis. The assay had high confidence (97%-
99%) for the mutated allele up to a mutation ratio of 5.9%
(Figure 2.2). Lower mutation ratios could not be assigned
as positive and were identified as false negative with a confi-
dence of 92%-98%. Thus our results indicated that HRM
analysis had a lower sensitivity than that of endonuclease
restriction analysis but had the benefit of identifying
different mutations in 1 PCR reaction.
IDH2 mutation analysis
The mutational frequency of IDH2 R140Q G>A was 6.69%
(16 out of 230 patients with AML), which was similar to the
frequency published by Paschka et al. [23] and other studies
[29,30]. Most patients with AML with IDH2 mutations were
older than 50 years and had de novo AML and a normal
karyotype. Of 16 patients, 7 had an NPM1mutation.
The ARMS analysis allowed differentiation between
mutated and wt DNA of IDH2 through specific differences
in the amplification properties of the reaction. In theanalysis of DNMT3A R882H G>A and R882X G>C mutations. Normalisation
o R882H. 2) Melting curve profiles of DNMT3A R882H G>A, R882X G>C and
e (dF/dT). R882H G>A displayed 2 peaks (84.5°C and 85.6°C), while the wt
Figure 4 ARMS analysis of IDH2 R140Q mutation. 1) Agarose gel analysis of PCR products of 3 positive (97, 107, 122) and 3 negative (94, 114, 126)
patients. All patients showed control (613 bp) and wt (233 bp) bands, while only the positive patients showed a product at 446 bp. Hyperladder II (Bioline)
was used as the marker. 2) Representative sequence analysis of patient 97 showing the heterozygote mutation CGG to CAG.
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ferent fragments with sizes 613 bp (control band), 446
(mutation band) and 233 bp (wt band, Figure 4.1). No
446 bp mutation band was detected in the wt samples and
results were confirmed by sequencing (Figure 4.2). InFigure 5 Melting curve profiles of wt allele and IDH2 140Q G>A. Verti
(dF/dT). IDH2 analysis showed a bimodal peak; R140Q was shifted to loweraddition some faint unspecific bands of size ≥613 bp were
detected. Given that the diagnostic approach was not
handicapped, the assay was acceptable for further applica-
tions. HRM screening of IDH2 showed no additional muta-
tions in our AML patient group. IDH2 amplificationcal axis corresponds to changes in the fluorescence signal over time
temperatures compared to the wt allele.
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79.8°C and a bigger peak at 82.7°C. Differences in mutated
and wt allele were visible during melting point analysis, be-
cause IDH2 R140Q mutations shifted to lower tempera-
tures than those in wt allele (Figure 5). Sensitivity tests
were performed as those described for DNMT3A. For the
IDH2 allele, the sensitivities of ARMS and HRM analyses
were the same, with a limitation at a mutational ratio of
2.25%. As shown in Figure 6.1 the mutation band at 446 bp
was not present in dilutions with 2.25% and 0.45% mutated
DNA. Furthermore, HRM analysis showed that dilutions
from 45% to 4.5% were clearly positive with a confidence
ranging from 77.68% to 98.41%, while the last 2 dilutions
were false-negative, with a confidence of 82% to 94.39%
(Figure 6.2).
IDH1 mutation analysis
An assay to detect specific mutations is not applicable be-
cause of the heterogeneity of IDH1 aberrations. Therefore,
the HRM assay was evaluated for IDH1, as previouslyFigure 6 Sensitivity analysis of IDH2 R140Q detection. 1) Serial dilution
sequencing). Mutated allele was detected up to a degree of 4.5%. 2) Difference
was possible up to a mutation ratio of 4.5%; lower mutation ratios were identifidescribed by Patel et al. [30]. Mutated and wt IDH1 was
distinguished through their melting profiles because mu-
tated DNA had a melting point between 80.3°C and 80.5°C
while wt IDH1 had a melting point of 81°C (Figure 7.1).
However, the distinction between the different mutations of
IDH1 was difficult with this analysis as well as with the dif-
ferentiation plot normalised to the wt control (Figure 7.2).
During this study we observed that the temperature-shifted
difference plot normalised to R132S C>A control sample
was the best to determine different IDH1 mutations
(Figure 7.3). Thus, we performed sensitivity tests for G105
C>T and R132C C>T with normalisation to R132S C>A
and for R132S C>A with normalisation to G105 C>T
(Figure 8). HRM analysis showed sensitivity of 6%-7.8% for
all three mutations. Using this method, we determined that
36 out of 230 (15.65%) patients with AML had IDH1 muta-
tions. Of these 19 (8.3%) had G105 C>T, 11 (4.8%) had
R132C C>T and 6 (2.6%) had R132S C>A; this frequency
is consistent with the data published by Nomdedéu
et al. [22,29].s of IDH2 R140Q: Undiluted mutation ratio was 45% (estimated by
plot for HRM analysis of serial dilutions of IDH2 R140Q: Correct estimation
ed false-negative. Normalisation was performed to the wt allele.
Figure 7 (See legend on next page.)
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Figure 7 HRM analysis of IDH1 mutations. 1) Melting curve profiles of IDH1 mutated and wt alleles. Vertical axis corresponds to changes in the
fluorescence signal over time (dF/dT). Mutated alleles were shifted to lower temperatures, but differentiation between different mutations was
not possible. 2) Difference plot for HRM analysis of IDH1 mutations normalised to wt allele, discrimination of different mutations was difficult
because of similar graphs. 3) Difference plot for HRM analysis of IDH1 mutations normalised to the R132S C>A allele, determination of different
mutations was easier because of clearly separated graphs.
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DNMT3A and IDH1/2 mutations in routine laboratory
analyses
Both the assays designed in this study for the detection
of DNMT3A R882H and IDH2 R140Q mutations were
completely compliant with Sanger sequencing and had a
high specificity. No false-positive results were determined
with HRM analysis. Two (0.9%) samples showed variations
for DNMT3A but were subsequently determined as wt by
endonuclease restriction and sequencing. IDH1 analysis
with HRM showed that 6 (2.6%) samples had inaccuracies
in melting profiles and hence were determined false nega-
tive with this method. Sequencing showed the presence of
a R132C C>T mutation in this samples. IDH2 analysis
showed no discrepancies with Sanger sequencing.
Compared to Sanger sequencing, HRM analysis rep-
resents a timesaving, cost-efficient and more sensitive
method to screen mutations in patients with AML at diag-
nosis. However, an efficient application presumes the pres-
ence of specific mutations and wt control samples.
Because of the lack of cell lines with DNMT3A, IDH2 and
IDH1 mutations, controls have to be established by se-
quencing different patient samples. Therefore, an effective
application of HRM depends on the identification of high
amounts of good-quality control samples, availability of a
sequencer and HRM competent real-time PCR cycler. In
addition, some results obtained with HRM analysis are dif-
ficult to interpret because of the variations in the melting
curve of 1 mutation and can lead to uncertain conclusions
or false-negative results [31]. Because new studies indicate
the prognostic significance of IDH1/2 and DNMT3A
mutations, which affect the choice of therapy, a steady
laboratory diagnosis is essential [10,17,18,21,22,32]. We
developed ARMS-PCR to identify IDH2 R140Q mutation
and endonuclease restriction analysis to identify DNMT3A
R882H mutations; both these methods are rapid and easy
to use and interpret. Thus, these methods can be used to
verify unclear results obtained using HRM analysis. In
addition, these methods provide a possibility to identify
the most common mutations in DNMT3A and IDH2 in
laboratories that do not have HRM-competent real-time
PCR cyclers at their disposal. Secondary endonuclease
restriction has higher sensitivity than HRM analysis that
allows earlier identification of mutations at relapse during
follow-up analysis [33]. For future applications this assay
could also be adapted to the quantitative PCR (qPCR)
technique. The forward primer can be modified to amplifyonly the genomic region containing the restriction position
that is lost in the mutated state, thus allowing the exclusion
of wt and mutated alleles as well as the quantitative assess-
ment of DNMT3A mutation. The main characteristics of
all the methods analysed in this study are summarised in
Table 1.
The measured sensitivities depend on assay conditions
and equipment. For example, small amounts of non-
specific amplicons and different salt or inhibitory concen-
trations can influence assay sensitivity [34,35]. Therefore,
each laboratory should validate the presented methods
with their equipment before application. Both HRM ana-
lysis and ARMS-PCR had only low sensitivity, which pos-
sibly could lead to false-negative results. Therefore, low
mutational ratios could be overlooked and these patients
would receive an imprecise laboratory diagnostic report.
Potential reduction of amplicon size for both HRM and
ARMS analyses could optimise sensitivities [36]. Moreover,
adaption of the qualitative endonuclease restriction assay
to a quantitative assay could further increase sensitivity
and provide objective measurements of mutated cells [37].
In the future, sensitivity limitations for screening
DNMT3A and IDH1/2 mutations can be overcome by
using allele-specific next-generation sequencing (NGS).
This method provides high multiplexing possibilities
together with high sensitivity and broad spectrum of de-
tected mutations [38]. However NGS is associated with
high costs, high hands-on time and high computational
expertise. Because standardisation and validation of NGS
can be challenging establishment of this method is an
ongoing process in laboratory routine [39]. Conventional
PCR-based methods are easy to standardise and validate
and therefore could be used when NGS is being imple-
mented in order to provide routine mutational screening
of patients with AML.
Possible laboratory workflow for identifying DNMT3A and
IDH1/2 mutations
Although Sanger sequencing is considered as the “gold
standard” for identifying mutations, this method is time-
consuming and cost-intensive in routine laboratory prac-
tice, because the diagnostic findings need to be available as
fast as possible. Based on the findings of this study, we de-
veloped a laboratory workflow for identifying IDH1/2 and
DNMT3A mutations in the first diagnosis and relapse with-
out using of sequencing (Figure 9). HRM analysis should be
the method of choice for differentiating between wt and all
Figure 8 (See legend on next page.)
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Figure 8 Sensitivity analysis of different IDH1 mutations. 1) Difference plot for HRM analysis of serial dilutions of IDH1 G105 C>T: Undiluted
mutation ratio was 51.9% (estimated by sequencing). Correct estimation was possible up to a mutation ratio of 7.8%; lower mutation ratios were
identified false-negative. Normalisation was performed to the R132S C>A allele. 2) Difference plot for HRM analysis of serial dilutions of IDH1
R132C C>T: Undiluted mutation ratio was 44.6% (estimated by sequencing). Correct estimation was possible up to a mutation ratio of 6.69%;
lower mutation ratios were identified false-negative. Normalisation was performed to the R132S C>A allele. 3) Difference plot for HRM analysis
of serial dilutions of IDH1 R132S C>A: Undiluted mutation ratio was 40.4% (estimated by sequencing). Correct estimation was possible up to a
mutation ratio of 6%, lower mutation ratios were identified false-negative. Normalisation was performed to the G105 C>T allele.










Sensitivity*, % 0.05 5.9 10 4.5 4.5 10 6 to 7.8 10
Turnaround time, days 1 1 2 to 3 1 1 2 to 3 1 2 to 3
Technician time, hours 4 3.5 10 to 12 3 3.5 10 to 12 3.5 10 to 12
Cost of diagnosis
method, €
32.13 28 122 44.16 28 122 28 122
Interpretation Easy Medium -difficult Medium Easy Medium -difficult Medium Medium -difficult Medium
Identification of
different/rare mutations
No Yes Yes No Yes Yes Yes Yes
Special equipment PCR cycler HRM real
time PCR cycler
Sequencer PCR cycler HRM real time
real time PCR cycler
Sequencer HRM real time
real time PCR cycler
Sequencer
*Sensitivity was measured as the minimal percentage of mutated allele in a sample detected by the assay.
Figure 9 Possible diagnostic workflow to identify DNMT3A, IDH2 and IDH1 mutations in routine laboratory analysis. HRM analysis can be
performed in the first diagnosis for all mutations because of high mutational ratios prior to therapy. Unclear results can be verified by endonuclease
restriction or ARMS-PCR. Unclear IDH1 results can be checked by sequencing because of the heterogeneity of possible mutations. Effective combination
of all the available methods enables more reliable results and a cost-effective and time-saving routine laboratory analysis.
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of uncertainty results can be verified using the above pre-
sented methods. In addition, ARMS and endonuclease re-
striction provide a possibility to identify the most common
IDH2 and DNMT3A mutations when no HRM-compatible
real-time PCR cycler is available. Because of the multiplicity
of IDH1 mutations, it was not possible to generate a valid
method for analysing 1 specific mutation. For this reason
HRM analysis is the best alternative to Sanger sequencing.
After therapy, follow-up analysis should be chosen depend-
ing on the identified mutations at the first diagnosis.
Because endonuclease restriction had higher sensitivity for
R882H mutations, this method is more suitable for detect-
ing low mutational ratio of known mutations in patients
after therapy or relapse and progression of disease. Because
of the ease of interpretation ARMS can also be used to
identify IDH2 R140Q mutations at relapse or disease
progression.Conclusion
In summary, we generated highly specific, sensitive and
rapid methods for identifying the most common muta-
tions in IDH2 (R140Q) and DNMT3A (R882H), which
can be used separately or in combination with HRM
analysis to provide more reliable diagnostic results. All
the developed methods were rapid, specific and easy to
use and interpret. PCR-based methods are a useful tool
for the routine laboratory identification of relevant prog-
nostic mutations. We propose that early screening of
mutations in patients with AML with normal karyotype
could facilitate risk stratification and improve treatment
opportunities.Additional files
Additional file 1: Table S1. Characteristics of patients with AML
according to mutation status.
Additional file 2: Table S2. Primers used in this study.
Additional file 3: PCR reaction mixtures and conditions.Abbreviations
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